Research progress in the relationship of apolipoprotein M with inflammatory diseases

doi:10.3969/j.issn.1673-8640.2018.03.015

Abstract

Abstract:

Apolipoprotein M （apo M） is a recently-discovered lipoprotein-associated plasma protein,which is highly expressed in liver and kidney. The expression of apo M is directly regulated by transcription factors,hormones,cytokines and other factors. Abnormal expression of apo M occurs frequently at inflammatory status. Further research on its features,regulation and effects of apo M is needed. The pathogenesis,diagnostic methods and treatment methods should be investigated. This review focuses on the recent research progress of apo M regulation and its relationship with inflammatory diseases.

Key words: Apolipoprotein M, Regulation, Inflammatory disease

CLC Number:

R446.1

GAO Jijuan, FANG Huanying. Research progress in the relationship of apolipoprotein M with inflammatory diseases[J]. Laboratory Medicine, 2018, 33(3): 252-258.

References 47

1	XU N,DAHLBÄCK B. A novel human apolipoprotein (apoM)[J]. J Biol Chem,1999, 274(44):31286-31290.
2	DAHLBÄCK B,NIELSEN L B. Apolipoprotein M-a novel player in high-density lipoprotein metabolism and atherosclerosis[J]. Curr Opin Lipidol,2006,17(3):291-295.
3	DUAN J,DAHLBÄCK B,VILLOUTREIX B O. Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis[J]. FEBS Lett,2001,499(1-2):127-132.
4	AXLER O,AHNSTRÖM J,DAHLBÄCK B. An ELISA for apolipoprotein M reveals a strong correlation to total cholesterol in human plasma[J]. J Lipid Res,2007,48(8):1772-1780.
5	胡志高,屈晓冰,胡敏. 载脂蛋白M与冠状动脉病变的关系[J]. 中国动脉硬化杂志,2008,16(3):224-226.
6	史清海,路西春. 载脂蛋白M的生物学特性及其研究进展[J]. 检验医学,2007,22(2):215-216.
7	WOLFRUM C,HOWELL J J,NDUNGO E,et al. Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M[J]. J Biol Chem,2008,283(24):16940-16949.
8	胡炎伟. Nur77影响apoE-/-小鼠动脉粥样硬化进展及相关机制研究[D]. 广州:南方医科大学, 2012.
9	任坤,唐振丽,易光辉. 载脂蛋白M[J]. 中国生物化学与分子生物学报,2015,31(6):557-565.
10	梁斌,白瑞,韩耀霞,等. 脂联素经肝X受体α途径对RAW 264.7巨噬细胞ABCG1表达的影响[J]. 生物化学与生物物理进展,2015,42(9):850-857.
11	朱兆金. 肝X受体激动剂T0901317对载脂蛋白M表达的影响[D]. 苏州:苏州大学,2008.
12	赵家仪,胡炎伟,郑磊,等. 二氢辣椒碱通过抑制Foxa2和增强LXRα下调HepG2细胞中ApoM的表达[J]. 中国动脉硬化杂志,2013,21(9):54.
13	VENTECLEF N,HARONITI A,TOUSAINT J J,et al. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1[J]. J Biol Chem,2008,283(7):3694-3701.
14	HUANG X S,ZHAO S P,HU M,et al. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation[J]. Med Hypotheses,2007,69(1):136-140.
15	王敏,罗光华,张晓膺. 载脂蛋白M-1-磷酸鞘氨醇轴与炎症相关性疾病关系的研究进展[J]. 临床检验杂志,2016,34(8):614-617.
16	GALVANI S,SANSON M,BLAHO V A,et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation[J]. Sci Signal,2015,8(389):ra79.
17	RUIZ M,FREJ C,HOLMÉR A,et al. High-density lipoprotein-associated apolipoprotein M limits endothelial inflammation by delivering sphingosine-1-phosphate to the sphingosine-1-phosphate receptor 1[J]. Arterioscler Thromb Vasc Biol,2017,37(1):118-129.
18	GAO J J,HU Y W,WANG Y C,et al. ApoM suppresses TNF-α-induced expression of ICAM-1 and VCAM-1 through inhibiting the activity of NF-κB[J]. DNA Cell Biol,2015, 34(8):550-556.
19	XU N, ZHANG X Y, DONG X, et al. Effects of platelet-activating factor, tumor necrosis factor,and interleukin-1 alpha on the expression of apolipoprotein M in HepG2 cells[J]. Biochem Biophys Res Commun,2002,292(4):944-950.
20	REN K,MO Z C,LIU X,et al. TGF-β down-regulates apolipoprotein M expression through the TAK-1-JNK-c-Jun pathway in HepG2 cells[J]. Lipids,2017,52(2):109-117.
21	SU W,JIAO G,YANG C,et al. Evaluation of apolipoprotein M as a biomarker of coronary artery disease[J]. Clin Biochem,2009,42(4-5):365-370.
22	ZHANG Y,HUANG L Z,YANG Q L,et al. Correlation analysis between ApoM gene-promoter polymorphisms and coronary heart disease[J]. Cardiovasc J Afr,2016,27(4):228-237.
23	LI H,LIU Y,WANG L,et al. High apolipoprotein M serum levels correlate with chronic obstructive pulmonary disease[J]. Lipids Health Dis,2016,15:59.
24	XU N, NILSSON-EHLE P, HURTIG M, et al. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo[J]. Biochem Biophysl Res Commun,2004,321(4):916-921.
25	BURKART K M,MANICHAIKUL A,WILK J B,et al. APOM and high-density lipoprotein are associated with lung function and per cent emphysema[J]. Eur Respir J,2014,43(4):1003-1017.
26	WU X,NIU N,BRISMAR K,et al. Apolipoprotein M promoter polymorphisms alter promoter activity and confer the susceptibility to the development of type 1 diabetes[J]. Clin Biochem, 2009,42(1-2):17-21.
27	NIU N,ZHU X,LIU Y,et al. Single nucleotide polymorphisms in the proximal promoter region of apolipoprotein M gene (apo M) confer the susceptibility to development of type 2 diabetes in Han Chinese[J]. Diabetes Metab Res Rev,2007,23(1):21-25.
28	PLOMGAARD P,DULLAART R P,DE VRIES R,et al. Apolipoprotein M predicts pre-beta-HDL formation:studies in type 2 diabetic and nondiabetic subjects[J]. J Intern Med, 2009,266(3):258-267.
29	ZHANG P,GAO J,PU C,et al. Effects of hyperlipidaemia on plasma apolipoprotein M levels in patients with type 2 diabetes mellitus:an independent case-control study[J]. Lipids Health Dis,2016,15(1):158.
30	NOJIRI T,KURANO M,TOKUHARA Y,et al. Modulation of sphingosine-1-phosphate and apolipoprotein M levels in the plasma,liver and kidneys in streptozotocin-induced diabetic mice[J]. J Diabetes Investig,2014,5(6):639-648.
31	ZHENG L,FENG Y,SHI Y,et al. Intralipid decreases apolipoprotein M levels and insulin sensitivity in rats[J]. PLoS One,2014,9(8):e105681.
32	XU N,AHRÉN B,JIANG J,et al. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells[J]. Biochim Biophys Acta,2006,1761(2):256-260.
33	罗光华. 载脂蛋白M在血糖调控中的应答反应机制及作用[D]. 苏州:苏州大学,2013.
34	CERVIN C,AXLER O,HOLMKVIST J,et al. An investigation of serum concentration of apo M as a potential MODY3 marker using a novel ELISA[J]. J Intern Med, 2010,267(3):316-321.
35	MUGHAL S A,PARK R,NOWAK N,et al. Apolipoprotein M can discriminate HNF1A-MODY from type 1 diabetes[J]. Diabet Med,2013,30(2):246-250.
36	SRECKOVIC I,BIRNER-GRUENBERGER R,BESENBOECK C,et al. Gestational diabetes mellitus modulates neonatal high-density lipoprotein composition and its functional heterogeneity[J]. Biochim Biophys Acta,2014,1841(11):1619-1627.
37	江华,罗光华,张俊,等. 血清载脂蛋白M水平在正常妊娠和妊娠糖尿病孕妇中的变化[J]. 中华内分泌代谢杂志,2014,30(9):727-730.
38	KUMARASWAMY S B,LINDER A,ÅKESSON P,et al. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes[J]. Crit Care, 2012,16(2):R60.
39	CHRISTOFFERSEN C,NIELSEN L B. Apolipoprotein M-a new biomarker in sepsis[J]. Crit Care,2012,16(3):126.
40	赵婷婷. 载脂蛋白M对细菌性肺炎的诊断和病情严重程度的判断价值[J]. 国际检验医学杂志,2015,37(5):588-590.
41	HU H J,JIN E H,YIM S H,et al. Common variants at the promoter region of the APOM confer a risk of rheumatoid arthritis[J]. Exp Mol Med,2011,43(11):613-621.
42	HUANG Y,LIU Y,JIANG L,et al. Apolipoprotein m (APOM) levels and APOM rs805297 G/T polymorphism are associated with increased risk of rheumatoid arthritis[J]. Joint Bone Spine,2014,81(1):32-36.
43	WANG Z,LUO G,FENG Y,et al. Decreased splenic CD4(+) T-lymphocytes in apolipoprotein M gene deficient mice[J]. Biomed Res Int,2015,2015:293512.
44	FEINGOLD K R,SHIGENAGA J K,CHUI L G,et al. Infection and inflammation decrease apolipoprotein M expression[J]. Atherosclerosis,2008,199(1):19-26.
45	古今刚. 乙型肝炎病毒对血浆载脂蛋白表达影响的研究及其机制探讨[D]. 武汉:武汉大学, 2013.
46	SVARRER E M,ANDERSEN H Ø,HELVIND M,et al. Urinary apolipoprotein M as a biomarker of acute kidney injury in children undergoing heart surgery[J]. Biomark Med,2016,10(1):81-93.
47	XU X L,MAO Q Y,LUO G H,et al. Urinary apolipoprotein M could be used as a biomarker of acute renal injury:an ischemia-reperfusion injury model of kidney in rat[J]. Transplant Proc,2013,45(6):2476-2479.

[1]	SUN Chuanyu, ZHAO Xiaojun, GE Shengyang, ZHANG Yang. Transcription factors in prostate cancer progression [J]. Laboratory Medicine, 2023, 38(9): 818-824.
[2]	FEI Bing, LIU Ying, REN Yanying, GUO Mengyu, LIU Xinwei, LIU Dongmei, LI Yongwei. Research progress of cyclic diguanylate on the regulation of Pseudomonas aeruginosa biofilm [J]. Laboratory Medicine, 2023, 38(2): 186-189.
[3]	WANG Zijin, ZHANG Xiaoying. Role of apolipoprotein M in the proliferation,migration and invasion of non-small cell lung cancer A549 cells [J]. Laboratory Medicine, 2020, 35(9): 937-942.
[4]	ZHANG Lihua, WANG Weiwei, ZHANG Liang, SHEN Lisong. Role of monocytic HLA-DR and CD16 determinations in inflammatory diseases [J]. Laboratory Medicine, 2018, 33(9): 775-780.
[5]	LIU Sichao, YAN Hongli. Correlation of angiogenesis regulation factors and oxidative stress markers with adverse pregnancy in preeclampsia patients [J]. Laboratory Medicine, 2018, 33(8): 686-691.
[6]	WU Yongqin, YING Chunmei. Drug resistance genes of Candida albicans to azoles and their regulation mechanisms [J]. Laboratory Medicine, 2016, 31(9): 739-743.
[7]	WEI Tingting, YANG Min, TANG Qingqin, ZHONG Renqian.. The research progress on long non-coding RNA in immune inflammatory reaction [J]. Laboratory Medicine, 2015, 30(10): 1044-1047.
[8]	FEI Fengying, YI Ping, LIN Jianmin.. Clinical application significance of serum amyloid A and C-reactive protein combined determination [J]. , 2014, 29(10): 1031-1033.
[9]	ZHAO Fuju，ZHAO Hu.. Research advancement in the molecular regulation mechanism on the expression of chromosomally-mediated AmpC beta-lactamase [J]. , 2014, 29(10): 1064-1068.